SANOFI exclusively provides Epilepsy and Bipolar medication to public sector patients
Diseases of the central nervous system (CNS) account for 7 of the 10 leading causes of disability in the world. One in five children and adolescents suffer from a mental disorder. In South Africa, HIV infection, substance use, and exposure to violence increase vulnerability to mental disorders. According to the Mental Federation of South Africa, more than 17 million people in South Africa are dealing with depression, substance abuse, anxiety, bipolar disorder and schizophrenia - illnesses that round out the top five mental health diagnoses.
Despite the high number, the Department of Health annually spends only 4% - or R9.3-billion - of its budget to address the crisis. A number of studies from across the globe suggest that mental health issues are on the rise in people who have HIV and AIDS. In fact, an analysis of these findings suggests that twice as many people with HIV have mental health issues than that of people without the disease.
Mental health problems in childhood and adolescence pose a major threat to public health. The first barriers to an equitable access to health care for people with mental illness are stigma and false beliefs. More than 50% of the cases of mental health begins in childhood. 75% of people with mental health do not receive appropriate treatment.
Sanofi generic’s leading scripted generic, supports seizure control while making access more affordable.
Sanofi’s anti- epileptic medications, along with other anti - epileptic medicines can help up to 70% of people with active Epilepsy to achieve satisfactory control.
- Improve access to care for people suffering from this neurological disease
- Creating an integrated approach when treating mental disorder patients with a huge focus on existing patient who are infected with HIV and AIDS